Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2.56M | $7.0M | 6.02% | +2.02M | 2026-06-30 |
| Vanguard Capital Management LLC | 1.68M | $5.0M | 3.93% | +235.9K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 1.43M | $4.0M | 3.35% | +232.5K | 2026-06-30 |
| Siren, L.L.C. | 1.06M | $3.0M | 2.50% | -- | 2026-06-30 |
| Geode Capital Management, LLC | 1.04M | $3.0M | 2.43% | +686.6K | 2026-06-30 |
| Mackenzie Financial Corp | 714.2K | $2.0M | 1.68% | -- | 2026-06-30 |
| Goldman Sachs Group Inc | 448.4K | $1.0M | 1.05% | +416.9K | 2026-06-30 |
| Marshall Wace, LLP | 439.6K | $1.0M | 1.03% | -248.6K | 2026-06-30 |
| Raymond James Financial Inc | 430.1K | $1.0M | 1.01% | +190.5K | 2026-06-30 |
| Globeflex Capital L P | 418.6K | $1.0M | 0.98% | -- | 2026-06-30 |
